Kidney damage in hypertension.Approaches for cardiovascular prevention
https://doi.org/10.18705/1607-419X-2010--5-
Abstract
A typical clinical case demonstrates how untreated hypertension can lead to fatal outcome through renal failure development. Modern approaches for cardiovascular prevention based on European and national guidelines are presented.
About the Author
О. О. Большакова
Almazov Federal Heart, Blood and Endocrinology Centre, St Petersburg
Russian Federation
Russian Federation
References
1. Guidelines for the management of arterial hypertension // J. Hypertens. - 2007. - Vol. 25, № 6. - P. 1105-1187.
2.
3. Диагностика и лечение артериальной гипертензии // Кардиоваск. терапия и профилактика. - 2008. - Т. 7, № 6, прил. 2
4.
5. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document // J. Hypertens. - 2009. - Vol. 27, № 11. - P. 2121-2158.
6.
7. Sasso F.C., Carbonara O., Persico M. et al. Irbesartan reduces the albumin escretion rate in microalbuminurid type 2 diabetic patients independently of hypertension // Diabetes Care. - 2002. - Vol. 25, № 11. - P. 1909-1913.
8.
9. Sasso F.C., De Nicola S., Carbonara O. et al. Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy // Diabetes Care. - 2006. - Vol. 29, № 3. - P. 498-503.
10.
11. Rossing K., Christensen P.K., Hovind P., Tarnow L., Rossing P., Parving H.H. Progression of nephropathy in type 2 diabetic patients // Kidney Int. - 2004. - Vol. 66, № 4. - P. 1596-1605.
12.
13. Parving H.-H., Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in patients with type 2 diabetes and microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes // N. Engl. J. Med. - 2001. - Vol. 345, № 12. - P. 870-878.
14.
15. Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N. Engl. J. Med. - 2001. - Vol. 345, № 12. - P. 851-860.
16.
17. Ribeiro A.B., Gavras H. Angiotensin II antagonists - clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria // Arq. Bras. Endocrinol. Metab. - 2006. - Vol. 50, № 2. - P. 327-333.
18.
19. Manley H.J. Role of angiotensin-converting-enzyme inhibition in patients with renal disease // Am. J. Health Syst. Pharm. - 2000. - Vol. 57, № 1. - P. S12-S18.
20.
21. Vaishya R., Singh J., Lal H. Biochemical effects of irbesartan in experimental diabetic nephropathy // Ind. J. Pharmacol. - 2009. - Vol. 41, № 6. - P. 252-254.
Review
For citations:
Большакова О.О. Kidney damage in hypertension.Approaches for cardiovascular prevention. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2010;16(5):523-525. (In Russ.) https://doi.org/10.18705/1607-419X-2010--5-
Views:
686
Email this article 